Targeting tumor cell motility to prevent metastasis

被引:181
作者
Palmer, Trenis D. [1 ]
Ashby, William J. [1 ]
Lewis, John D. [2 ]
Zijlstra, Andries [1 ]
机构
[1] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA
[2] London Hlth Sci Ctr, London Reg Canc Program, London, ON N6A 4L6, Canada
基金
美国国家卫生研究院;
关键词
Migration; Metastasis; Motility; Therapy; Tumor; Adhesion; Invasion; Intravasation; BREAST-CANCER METASTASIS; FOCAL ADHESION KINASE; NF-KAPPA-B; TGF-BETA; PHASE-II; MATRIX METALLOPROTEINASES; MESENCHYMAL TRANSITION; EXTRACELLULAR-MATRIX; TETRASPANIN PROTEINS; MONOCLONAL-ANTIBODY;
D O I
10.1016/j.addr.2011.04.008
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Mortality and morbidity in patients with solid tumors invariably result from the disruption of normal biological function caused by disseminating tumor cells. Tumor cell migration is under intense investigation as the underlying cause of cancer metastasis. The need for tumor cell motility in the progression of metastasis has been established experimentally and is supported empirically by basic and clinical research implicating a large collection of migration-related genes. However, there are few clinical interventions designed to specifically target the motility of tumor cells and adjuvant therapy to specifically prevent cancer cell dissemination is severely limited. In an attempt to define motility targets suitable for treating metastasis, we have parsed the molecular determinants of tumor cell motility into five underlying principles including cell autonomous ability, soluble communication, cell-cell adhesion, cell-matrix adhesion, and integrating these determinants of migration on molecular scaffolds. The current challenge is to implement meaningful and sustainable inhibition of metastasis by developing clinically viable disruption of molecular targets that control these fundamental capabilities. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:568 / 581
页数:14
相关论文
共 182 条
[1]
Src family tyrosine kinases and growth factor signaling [J].
Abram, CL ;
Courtneidge, SA .
EXPERIMENTAL CELL RESEARCH, 2000, 254 (01) :1-13
[2]
SRC: A Century of Science Brought to the Clinic [J].
Aleshin, Alexey ;
Finn, Richard S. .
NEOPLASIA, 2010, 12 (08) :599-607
[3]
Jekyll and Hyde: the role of the microenvironment on the progression of cancer [J].
Allen, Michael ;
Jones, J. Louise .
JOURNAL OF PATHOLOGY, 2011, 223 (02) :162-176
[4]
Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium [J].
Alva, Ajjai ;
Slovin, Susan ;
Daignault, Stephanie ;
Carducci, Michael ;
DiPaola, Robert ;
Pienta, Ken ;
Agus, David ;
Cooney, Kathleen ;
Chen, Alice ;
Smith, David C. ;
Hussain, Maha .
INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) :749-757
[5]
p120-ctn: A nexus for contextual signaling via Rho GTPases [J].
Anastasiadis, Panos Z. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2007, 1773 (01) :34-46
[6]
[Anonymous], LANCET
[7]
[Anonymous], CD151 UCSD NATURE MO
[8]
[Anonymous], TETRASPANINS CANC CE
[9]
[Anonymous], CURR OPIN CELL BIOL
[10]
[Anonymous], NEOPLASTIC DIS TXB T